Humana (HUM) stock has been stagnant, lowering full-year earnings outlook due to Medicare Advantage headwinds. A potential pharmacy partnership with Mark Cuban could boost growth, following an increase in Q3 2025 revenue to $32.6 billion. CenterWell, serving 447,100 patients, shows promise with 18.9% revenue contribution. Analysts rate HUM stock a “Moderate Buy” with a mean price target of $283.61. Jefferies upgraded Humana to “Buy” on strong earnings growth potential. Expectations for margin expansion and cash flow improvement position Humana well for future growth and dividend increases.

Read more at Barchart: Humana Stock Is Nearly 20% Off Its YTD Highs. Can Mark Cuban Change That?